ProSci SARS-CoV-2 (COVID-19) NSP16 Peptide

Catalog No.	Quantity
16-595-389	0.05 mg

Catalog No. 16-595-389 Supplier ProSci Supplier No. 9271P0050

Description

Used for Blocking Activity

SARS-CoV-2 (COVID-19) NSP16 Peptideis used for blocking the activity of theSARS-CoV-2 (COVID-19) NSP16 Antibody

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019-20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Methyltransferase mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.

Specifications

• Gene ID (Entrez): 43740578
• Species: SARS-CoV-2
• Accession Number: YP_009725311
• Common Name: ORF1a polyprotein;ORF1ab polyprotein
• Concentration: 200 μg/mL
• Content And Storage: Store SARS-CoV-2 (COVID-19) NSP16 Peptide at -20°C, stable for one year.
• Format: Liquid
• Formulation: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide
• For Use With (Application): Blocking Assay
• Gene Symbol: NSP16
• Quantity: 0.05 mg
• Sequence: 16 amino acids near the central domain of SARS-CoV-2 (COVID-19) NSP16.
• Synonym: 2 ';-O-methyltransferase, nsp16, Non-structure protein 16